131J-speichernde pulmonale und ossäre Metastasen differenzierter Schilddrüsenkarzinome bei niedrigem Serum-Thyreoglobulinspiegel – Ausnahme in der Tumornachsorge?

1987 ◽  
Vol 26 (03) ◽  
pp. 139-142 ◽  
Author(s):  
G. Arning ◽  
O. Schober ◽  
H. Hundeshagen ◽  
Ch. Ehrenheim
Keyword(s):  
Serum Level ◽  
Thyroid Carcinoma ◽  
Bone Metastases ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Level ◽  
Low Serum

In the follow-up of differentiated thyroid carcinoma it is discussed whether the tumormarker thyroglobulin can replace the1311 scan, especially when the thyroglobulin serum level is normal. A positive1311 scan of metastases in the follow-up of patients with differentiated thyroid carcinoma combined with a low serum thyroglobulin level is extremely rare. The literature shows a frequency of about 4%. Recently we found 3 cases with a positive1311 scan demonstrating pulmonary and bone metastases whereas the serum thyroglobulin level was low.

The usefulness of serum thyroglobulin in the follow-up of differentiated thyroid carcinoma in children

1992 ◽  
Vol 20 (3) ◽  
pp. 201-208 ◽  
Author(s):  
Jeremy M. W. Kirk ◽  
Catherine Mort ◽  
David B. Grant ◽  
Richard J. Touzel ◽  
Nicholas Plowman
Keyword(s):  
Thyroid Carcinoma ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin

scholarly journals The significance of simultaneous measurement of serum thyroglobulin and thyroglobulin antibody during the follow up of patients with differentiated thyroid carcinoma

2011 ◽  
Vol 152 (19) ◽  
pp. 743-752
Author(s):  
Zoltán Lőcsei ◽  
Dóra Horváth ◽  
Károly Rácz ◽  
Erzsébet Toldy
Keyword(s):  
Thyroid Carcinoma ◽  
Antibody Level ◽  
Differentiated Thyroid Carcinoma ◽  
Review Literature ◽  
Antibody Concentration ◽  
Serum Samples ◽  
Serum Thyroglobulin ◽  
Thyroglobulin Antibody ◽  
Current Guidelines

Serum thyroglobulin is an essential marker during the follow-up of patients with differentiated thyroid carcinoma. Demonstration of the total absence of thyroglobulin is not possible by immunoanalytic methods if thyroglobulin antibody is present in serum samples that occur in almost 20% of patients with differentiated thyroid carcinoma. Therefore, current guidelines recommend estimation of thyroglobulin levels only if quantitative level of thyroglobulin antibody is known. However, normal thyroglobulin antibody level fails to exclude interference with the antibody, because antibody concentration within the normal range may interfere with the thyroglobulin assay. In this respect recommendations are not consistent because they distinguish only occasionally cases with normal and those with non-detectable serum thyroglobulin level. In addition, the possible impact of normal thyroglobulin antibody level on the thyroglobulin assay has not been entirely explored. Authors review literature data and current guidelines on the analytical and preanalytical limitations of the thyroglobulin and thyroglobulin antibody measurements. On the basis of their own studies, authors make recommendation for improvement of the diagnostic accuracy of the thyroglobulin measurement. Orv. Hetil., 2011, 152, 743–752.

How to deal with undetectable and low measurable serum thyroglobulin levels in the follow-up of patients with differentiated thyroid carcinoma?

1985 ◽  
Vol 110 (4) ◽  
pp. 487-492 ◽  
Author(s):  
Matti Välimäki ◽  
Bror-Axel Lamberg
Keyword(s):  
Thyroid Carcinoma ◽  
Neck Region ◽  
Differentiated Thyroid Carcinoma ◽  
Whole Body ◽  
Cancer Tissue ◽  
Serum Thyroglobulin ◽  
Before And After ◽  
Measurable Serum

Abstract. Serum thyroglobulin (Tg) was measured in 52 patients 3 months to 15 years (mean 5.3 years) after thyroidectomy with or without subsequent radioablation for differentiated thyroid carcinoma, before and after the interruption of suppressive thyroxine (T4) replacement therapy for 5 weeks. Whole body scintigraphy was carried out at the end of the T4 withdrawal period. Serum Tg was undetectable (< 3 μg/l) in 38 patients on T4 therapy, in 18 the scintigraphy showed a minimal accumulation in the neck region and in 20 no uptake anywhere after withdrawal of T4. In the former group Tg rose in 10 patients to 4–21 μg/l when off T4 which seemed to correspond to the normal tissue left in situ, in the latter group Tg rose only in 2 patients to 5 and 21 μg/l, respectively. Two patients out of 14 with detectable Tg on T4 had pulmonary metastases as uncovered by whole body scintigraphy (in one of them Tg rose from 12 μg/l on T4 to 1200 μg/l off T4) and 6 patients were suspected for having recidual cancer tissue (2 patients had a negative scintigraphy) because the Tg rose (66– 215 μg/l) over the upper limit of the reference range (< 50 μg/l) after T4 withdrawal. In conclusion, in the follow-up of patients with differentiated thyroid carcinoma no routine scans are needed as long as serum Tg remains undetectable but further examinations are shortly warranted when detectable Tg is obtained during T4 suppression.

Rising serum thyroglobulin in the follow-up of patients with differentiated thyroid carcinoma: the role of FDG PET-CT

2014 ◽  
Author(s):  
Paulina Godlewska ◽  
Elzbieta Bruszewska ◽  
Grazyna Lapinska ◽  
Agnieszka Fijolek-Warszewska ◽  
Marek Dedecjus
Keyword(s):  
Thyroid Carcinoma ◽  
Fdg Pet ◽  
Differentiated Thyroid Carcinoma ◽  
Serum Thyroglobulin ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Expression and Prognostic Value of α-, β-, andγ -Catenins in Differentiated Thyroid Carcinoma

2000 ◽  
Vol 85 (12) ◽  
pp. 4806-4811
Author(s):  
Jan Böhm ◽  
Leo Niskanen ◽  
Kari Kiraly ◽  
Jari Kellokoski ◽  
Matti Eskelinen ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Prognostic Value ◽  
Prognostic Significance ◽  
Differentiated Thyroid Carcinoma ◽  
Primary Treatment ◽  
Serum Thyroglobulin ◽  
Free Survival ◽  
Thyroglobulin Level ◽  
Traditional Risk Factors ◽  
Related Mortality

Catenins (α, β, and γ) are a group of intracellular cell adhesion molecules that unite cytoskeleton with extracellular adhesion system. Abnormal expression of these molecules may have prognostic relevance in various carcinomas, including differentiated thyroid carcinoma (DTC). We have, therefore, evaluated the prognostic value of α-, β-, andγ -catenins along with traditional risk factors in 206 consecutive DTC patients by immunohistochemistry. Papillary carcinomas showed normal staining pattern for α-, β-, andγ -catenins in 124 (60%), 136 (67%), and 94 (46%) cases, respectively. Follicular carcinomas expressed α-, β-, andγ -catenins normally in 16 (48%), 18 (55%), and 8 (32%) cases, respectively. Follicular type of tumor showed more often reduced staining for all catenins than papillary carcinoma (P = 0.009, P = 0.004, and P = 0.002, respectively). Age (&gt;60 yr) and pTNM-stage were related to reduced α- and β-catenin expression levels (P = 0.027 and P = 0.026, respectively) and larger size of the tumor to reduced β- andγ -catenin expressions (P = 0.039 and P = 0.007, respectively). Nodal metastases at the time of primary treatment related to reduced α-catenin expression and distal metastases to reduced β- and γ-catenin staining signals (P = 0.022, P = 0.014, and P = 0.039, respectively). Reduced α-catenin associated with tumor recurrence (P = 0.002) and reduced β-catenin with cancer-related mortality (P = 0.005). The multivariate analysis for recurrence-free survival showed that α-catenin and serum thyroglobulin level 1 yr after primary treatment were prognostic of recurrent disease (hazards ratio, 3.42, P = 0.022; and hazards ratio, 10.03, P = 0.0001). In addition,α -catenin retained its prognostic significance in low-stage patients (P = 0.0151). We propose that the evaluation ofα -catenin expression by immunohistochemistry in DTC patients has prognostic value in addition to that obtained by traditional prognostic factors.

Sign in / Sign up

Export Citation Format

Share Document